On June 8, 2020 local time, Haifa, Israel, researchers worked in the laboratory of Pluristem Therapeutics. Pluristem Therapeutics is a clinical-stage regenerative medicine company that uses placental cells and a unique, proprietary three-dimensional technology platform to develop cell therapies to treat inflammation, ischemia, muscle damage, blood diseases, and radiation. The Haifa-based company has received 50 million euros (about 400 million yuan) from the European Union’s European Investment Bank (EIB) to promote its pioneering regenerative cell therapy platform and focus on In the clinical development of placental cell-based therapy for the treatment of new coronary pneumonia-related complications.

Release time: 2020-06-13 17:24:06 [Editor: Zhai Lu]